MyFinsight
Home
Blog
About
Marketable securities
$557,937K
(-10.97%↓ Y/Y)
Trade receivables,
net
$322,213K
(10.21%↑ Y/Y)
Cash and cash
equivalents
$281,448K
(71.16%↑ Y/Y)
Prepaid expenses and
other current assets
$60,495K
(-18.06%↓ Y/Y)
Inventory
$28,729K
(22.34%↑ Y/Y)
Total current assets
$1,250,822K
(5.93%↑ Y/Y)
Non-current marketable
securities
$544,930K
(-8.36%↓ Y/Y)
Deferred tax assets, net
$294,205K
(-29.82%↓ Y/Y)
Right-of-use assets and other
non-current assets
$247,928K
(-19.87%↓ Y/Y)
Property and equipment,
net
$92,665K
(-16.00%↓ Y/Y)
Goodwill
$63,684K
(0.00%↑ Y/Y)
Total assets
$2,494,234K
(-6.86%↓ Y/Y)
Total liabilities and
stockholders equity
$2,494,234K
(-6.86%↓ Y/Y)
Total stockholders
equity
$1,843,762K
(-9.33%↓ Y/Y)
Total liabilities
$650,472K
(0.92%↑ Y/Y)
Accumulated deficit
-$262,533K
(-19.58%↓ Y/Y)
Accumulated other
comprehensive income (loss)
-$2,013K
(-249.22%↓ Y/Y)
Additional
paid-in-capital
$2,108,059K
(-6.37%↓ Y/Y)
Total current
liabilities
$361,927K
(7.68%↑ Y/Y)
Non-current operating lease
liabilities
$165,929K
(-7.74%↓ Y/Y)
Other non-current
liabilities
$122,616K
(-4.65%↓ Y/Y)
Common stock, 0.001 par
value 400,000 shares...
$249K
(-7.78%↓ Y/Y)
Other current
liabilities
$102,662K
(1.28%↑ Y/Y)
Accrued compensation
and benefits
$68,629K
(-5.01%↓ Y/Y)
Rebates and fees due to
customers
$66,711K
(16.47%↑ Y/Y)
Accrued clinical trial
liabilities
$59,767K
(3.27%↑ Y/Y)
Accounts payable
$39,062K
(51.28%↑ Y/Y)
Accrued collaboration
liabilities
$25,096K
(16.59%↑ Y/Y)
Back
Back
Balance Sheet
Exelixis-Logo-2023-svg
EXELIXIS, INC. (EXEL)
Exelixis-Logo-2023-svg
EXELIXIS, INC. (EXEL)
source: myfinsight.com